Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J
Fuente:
FierceBiotech
Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals phase 1 asset for patients with metabolic dysfunction-associated steatohepatitis (MASH).